Comprehensive urine drug profiles
Expert-backed testing to monitor therapy, assess risk, and identify misuse
Mayo Clinic Laboratories’ controlled substance monitoring profiles were developed by the Clinical and Forensic Toxicology Laboratory at Mayo Clinic and are consistent with laboratory medicine practice guidelines established by the American Association for Clinical Chemistry (AACC),2 which were endorsed by the American Academy of Pain Medicine (AAPM). The results of these assays can be used to guide pharmacotherapy decisions while ensuring prescribing adherence to federal and state guidelines through compliance monitoring.
Specimen validity testing
Effective monitoring of controlled substances and assessment for risk of misuse requires correct interpretation of test results. Because adulterated specimens can generate inaccurate results, having potentially damaging effects on treatment decisions, specimen validity testing is important to assess sample quality prior to testing and result interpretation.
Approximately eight percent of samples received at Mayo Clinic Laboratories for controlled substances monitoring were identified as adulterated.
Our controlled substance monitoring profiles begin with an adulterant survey to assess for common masking agents and ensure specimen quality. When adulterated specimens are identified, the test order is canceled and reported as invalid, free of charge to the client.
Interpretive reports
Laboratory-generated test results are accompanied by interpretive reports that clearly identify the presence of prescribed, nonprescription, and illicit drugs. By including testing limitations, details on the window of drug detection, and information on the presence of pharmaceutical impurities and metabolic breakdowns of parent drugs, these enhanced reports provide important insights to guide treatment decisions
Our industry-leading experts are available to discuss unexpected or unexplained results, provide ordering guidance, and offer testing education free of charge to our clients.
Comprehensive URINE drug profiles TEST MENU for Pain Management
Comprehensive Urine drug profiles
Commonly prescribed benzodiazepines (e.g., alprazolam, clonazepam), opioids (e.g., hydrocodone, oxycodone, methadone), and stimulants (e.g., methylphenidate, amphetamine) present challenges for clinicians due to their high risk of misuse, abuse, and diversion.1
Key testing
- CSMEU | Controlled Substance Monitoring Enhanced Profile with Reflex, 21 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
- Identifies drug use involving alcohol, amphetamines, barbiturates, benzodiazepines, cocaine, opioids, PCP, and COOH-THC.
- Detects spiked samples.
- Please note: If the limited immunoassay screen is positive in this profile (Mayo ID: CSMEU), confirmation with quantification of presumptive positives for barbiturates, ethanol, cocaine and metabolites, and/or tetrahydrocannabinol metabolite will be performed at an additional charge.
- CSMPU | Controlled Substance Monitoring Panel, Random, Urine
- Identifies drug use involving amphetamines, barbiturates, benzodiazepines, cocaine, opioids, phencyclidine (PCP) and carboxy-tetrahydrocannabinol (COOH-THC).
- Detects spiked samples.
- Please note: If the limited immunoassay screen is positive in this profile (Mayo ID: CSMPU), confirmation with quantification of presumptive positives for barbiturates, cocaine and metabolites, and/or tetrahydrocannabinol metabolite will be performed at an additional charge. If the quantification of presumptive positive results is not required, refer to Controlled Substance Monitoring Hybrid Drug Profile, High-Resolution Mass Spectrometry, and Immunoassay Screen, Random, Urine (Mayo ID: CSMHU).
- CSMTU | Controlled Substance Monitoring Targeted Profile, 17 Drug Classes, Mass Spectrometry, Random, Urine
- Identifies drug use involving amphetamines, benzodiazepines, opioids, and PCP where immunoassays are not adequate.
- Detects spiked samples.
References
- Preuss CV, Kalava A, King KC. Prescription of controlled substances: benefits and risks. Treasure Island, FL: StatPearls Publishing; 2019.
- Jannetto PJ, Bratanow NC, Clark WA, et al. Executive Summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline — Using Clinic Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. J Applied Lab Med. 2018;2(4):489-526.